Elizabeth Kinter

Bio:

Dr. Elizabeth Kinter currently is the Head of Commercial at Avidity Biosciences, a Novartis Company. She joined Avidity as the Head of Market Access and HEOR, building the team and infrastructure to prepare for launching 3 drugs over 18 months.

She started her career in industry at Biogen in Global Health Economics for the Multiple Sclerosis Franchise. Over her 10 years at Biogen, she transitioned to market access roles where she lead the European Market Access Team for the Multiple Sclerosis Franchise, Global Neuroscience Access Team and the U.S. Market Access Strategy and Pricing Team.  During her tenure at Biogen, she launched 7 new products and lead numerous pricing and reimbursements assessments for the established brands.  She joined Takeda to lead the Global Access Strategy Team across the marketed brands and pipeline functions and preparing the company for implementation of the Inflation Reduction Act and potential impact across the portfolio. Dr. Kinter joined Vir Bio as the Head of Evidence Value and Access and transitioned to the Head of Commercial, building and preparing the company to evolve from a clinical to commercial stage. She received her Masters in Health Policy and PhD in Health Economics from the Johns Hopkins Bloomberg School of Public Health.